A consortium of prostate cancer experts have discovered, through a clinical investigation, that prostate cancer patients who have a lower prostate specific antigen (PSA) score after radiation therapy to treat their cancer are less likely to have their prostate cancer return or spread to other parts of their body than patients with a higher PSA score.
The study was published in the March 15, 2006, issue of the International Journal of Radiation Oncology-Biology-Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.
The study was conducted on nearly 5,000 patients treated with radiation therapy in nine prestigious academic radiation oncology departments across the United States. The participating institutions included the University of Michigan in Ann Arbor, Mich.; the M.D. Anderson Cancer Center in Houston; Fox Chase Cancer Center in Philadelphia; Cleveland Clinic Foundation in Cleveland; William Beaumont Hospital in Royal Oak, Mich.; Mallinckrodt Institute of Radiology in St. Louis; Mayo Clinic College of Medicine in Rochester, Minn.; Massachusetts General Hospital in Boston and Memorial Sloan-Kettering Cancer Center in New York.
After receiving radiation, most patients experience a decline in their PSA blood test score. Doctors measure the PSA level after radiation to monitor treatment response. If the PSA decreases and then stays relatively level, the treatment is considered a success, but if the PSA then rises, doctors may consider additional treatments for cancer recurrence.
In this study, researchers set out to examine whether or not a lower PSA score is a good indicator in predicting the likelihood that a patient’s prostate cancer will return or spread. In the current standard of care, doctors are less interested in the actual PSA score, but whether the PSA rises after treatment. A rise is used to gauge whether the cancer will likely return.